Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2025 / October / Seaport Criteria Bring Clarity to Myocarditis Grading / Notecards
Guidelines and Recommendations Microbiology and Immunology Screening and monitoring

Seaport Criteria Bring Clarity to Myocarditis Grading

New guidelines combine hematoxylin and eosin and CD3 staining to improve diagnostic accuracy and reproducibility worldwide

10/10/2025 News 2 min read
article Full Article Summary Notecard

Share

  1. Seaport criteria classify lymphocytic myocarditis into mild, moderate, and severe grades.

  2. Diagnosis is based on T lymphocyte identification using CD3 immunohistochemistry.

  3. Mild myocarditis requires either a single cluster of 5+ lymphocytes or 15 non-clustered CD3+ cells.

  4. Moderate myocarditis requires two or more lymphocyte clusters.

  5. Severe myocarditis shows multifocal or diffuse infiltrates with myocyte injury.

  6. Developed through a 3-year Delphi process involving pathologist feedback.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.